Drug Trial Radar · NCT02763319
A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Last checked: Nov 20, 2026Latest source record: Jul 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
453
Actual
Start
Nov 28, 2016
Primary completion
Jun 21, 2024
Study completion Jun 21, 2024
Sponsor
- Lead sponsor
- Incyte CorporationIncyte (INCY)
- Sponsor type
- Industry
- First posted
- May 5, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to compare the safety and efficacy of Tafasitamab with BEN versus RTX with BEN in adult patients with relapsed of refractory DLBCL.
Conditions
- Diffuse Large B-cell Lymphoma
Interventions
Rituximab (RTX)Drug
Rituximab: Dose: 375 mg/m2 IV
TafasitamabDrug
Tafasitamab: Tafasitamab dose: 12 mg/kg intravenously (IV)
Bendamustine (BEN)Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Kaplan-Meier Estimate of Progression-Free Survival by Independent Radiology/Clinical Review Committee Assessment in the Overall PopulationTime frame: up to 41.4 months
- Kaplan-Meier Estimate of Progression-Free Survival by Independent Radiology/Clinical Review Committee Assessment in the Natural Killer Cell Count-Low SubgroupTime frame: up to 46.5 months
Locations
158 sites in 23 countries. Site status is shown where the registry gives one.
MorphoSys Research Site
Anaheim, California
MorphoSys Research Site
Bakersfield, California
Morphosys Research Site
Burbank, California
Morphosys Research Site
Fresno, California
MorphoSys Research Site
Los Angeles, California
MorphoSys Research Site
Whittier, California
MorphoSys Research Site
Plainville, Connecticut
MorphoSys Research Site
Skokie, Illinois
MorphoSys Research Site
Detroit, Michigan
MorphoSys Research Site
Rochester, Minnesota
MorphoSys Research Site
Hattiesburg, Mississippi
Morphosys Research site
Jackson, Mississippi
Morphosys Research Site
Morristown, New Jersey
MorphoSys Research Site
New York, New York
MorphoSys Research Site
Stony Brook, New York
MorphoSys Research Site
Oklahoma City, Oklahoma
MorphoSys Research Site
Knoxville, Tennessee
Morphosys Research Site
Lubbock, Texas
MorphoSys Research Site
Adelaide, Australia
MorphoSys Research Site
Albury, Australia
MorphoSys Research Site
Bedford Park, Australia
MorphoSys Research Site
Box Hill, Australia
MorphoSys Research Site
Concord, Australia
MorphoSys Research Site
Frankston, Australia
MorphoSys Research SIte
Garran, Australia
MorphoSys Research Site
Geelong, Australia
MorphoSys Research Site
Gosford, Australia
MorphoSys Research Site
Nedlands, Australia
MorphoSys Research Site
South Brisbane, Australia
MorphoSys Research Site
St Albans, Australia
MorphoSys Research Site
Innsbruck, Austria
MorphoSys Research Site
Saskatoon, Canada
Morphosys Research Site
Edmonton, Alberta, Canada
MorphoSys Research Site
Winnipeg, Manitoba, Canada
MorphoSys Research Site
Saint John, New Brunswick, Canada
Morphosys Research Site
St. John's, Newfoundland and Labrador, Canada
MorphoSys Research Site
Kingston, Ontario, Canada
MorphoSys Research Site
Greenfield Park, Quebec, Canada
Morphosys Research Site
Montreal, Quebec, Canada
MorphoSys Research Site
Zagreb, Croatia
Showing 40 of 158 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.